Robert D. Newman

Robert D. Newman

Auto-generated profile, based on publicly available information

Robert D. Newman

Malaria Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KKKassoum Kayentao
Kassoum Kayentao
MKMamoudou Kodio
Mamoudou Kodio
RNRobert D. Newman
Robert D. Newman
Hamma MaigaHamma Maiga
Hamma Maiga
DDDidier Doumtabe
Didier Doumtabe
ODOgobara Doumbo
Ogobara Doumbo
Background. Malaria during pregnancy contributes to maternal anemia and low birth weight. In East Africa, several studies have demonstrated that intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) is more efficacious than weekly chloroquine (CQ) chemoprophylaxis in preventing these adverse consequences. To our knowledge, there are no published trials evaluating IPT in West Africa. Methods. We undertook a randomized controlled trial of weekly CQ chemoprophylaxis, 2-dose IPT with CQ, and 2-dose IPT with SP; 1163 women were enrolled. Results. In multivariate analyses, when compared with weekly CQ, IPT/SP was associated with a reduction in third-trimester anemia (adjusted odds ratio [AOR], 0.49; P = .001), placental parasitemia (AOR, 0.69; P = .04), and low birth weight (2 doses may be required to prevent placental reinfection prior to delivery.

4 June 2003 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
RNRobert D. Newman
Robert D. Newman
MPMonica E. Parise
Monica E. Parise
LSLaurence Slutsker
Laurence Slutsker
BNBernard Nahlen
Bernard Nahlen
RSRichard W. Steketee
Richard W. Steketee
Summary: Plasmodium falciparum malaria in pregnancy poses substantial risk to a pregnant woman and her neonate through anaemia and low birth weight (LBW), respectively, and is responsible for up to 35% of preventable LBW in malaria‐endemic areas. Chemoprophylaxis or intermittent preventive treatment (IPT) with an effective antimalarial can ameliorate the adverse effects of malaria during pregnancy. Current guidelines from the WHO recommend that women in highly malarious areas receive IPT with an effective antimalarial. Two central considerations in evaluating drugs for use during pregnancy are safety for the mother and her foetus and effectiveness, which is determined by efficacy, cost, availability, deliverability and acceptability of the drug. These factors may be scored and potential drugs or drug combinations ranked in order of potential effectiveness for use in prevention programmes. The seven most promising regimens are all IPT, primarily because they are more easily delivered and less expensive than chemoprophylaxis. Currently, IPT with sulphadoxine–pyrimethamine (SP) is more likely to have the best overall effectiveness in preventing adverse outcomes associated with malaria in pregnancy. Its low cost, wide availability, easy deliverability and acceptability make it the clear choice in countries where efficacy of the drug remains good. For countries where resistance to SP is rising or already high, amodiaquine (alone or in combination with SP or artesunate) artesunate + SP, chlorproguanil–dapsone (with and without artesunate) and artemether–lumefantrine require urgent evaluation for use in pregnancy.

8 June 2007
Verified
Journal Article
Closed access
JTJulie Thwing
Julie Thwing
JSJacek Skarbinski
Jacek Skarbinski
RNRobert D Newman
Robert D Newman
ABAnn M Barber
Ann M Barber
SMSonja Mali
Sonja Mali
PAPaul M Arguin
Paul M Arguin

14 March 2006 in Tropical Medicine & International Health
Verified
Journal Article
Closed access
PDF file
RNRobert D. Newman
Robert D. Newman
AMAllisyn C. Moran
Allisyn C. Moran
KKKassoum Kayentao
Kassoum Kayentao
EBElizabeth Benga-De
Elizabeth Benga-De
MYMathias Yameogo
Mathias Yameogo
RSRichard W. Steketee
Richard W. Steketee

25 July 2003
Verified
Journal Article
Closed access
CYChun Yang
Chun Yang
MLMo Li
Mo Li
RNRobert D Newman
Robert D Newman
YSYa Ping Shi
Ya Ping Shi
JAJohn G Ayisi
John G Ayisi
RLR Lal
R Lal
Little is known about the impact of HIV-1 group M subtypes on mother-to-child transmission (MTCT) of HIV-1 in African settings where multiple HIV-1 group M subtypes are co-circulating. To assess the role of subtype variation on MTCT. HIV-1-infected women attending an antenatal clinic in western Kenya were enrolled for a prospective study (1996-2000) of MTCT. HIV-1 subtype analysis of p24gag and gp41env identified potential recombinants, and their role in MTCT was determined. Among 414 women for whom HIV-1 subtype and HIV transmission status were available, MTCT occurred in 80 (19.3%). MTCT rates were higher among women with subtype D compared with subtype A in either the gp41 region [31.6 versus 16.1%, relative risk (RR) 2.0, P=0.002] or p24 region (29.9 versus 18.0%, RR 1.7, P=0.02). Discordant subtype combinations were identified in 103 of the women (25.9%), and were associated with higher rates of MTCT (28.2 versus 17.0%, RR 1.7, P=0.01). In multivariate analysis, women with subtype combinations D/D, D/A, and A/D had an increased risk of MTCT (adjusted odds ratios 3.5, 2.5, 6.2; P=0.005, 0.05, and 0.0003, respectively) compared with A/A women after adjustment for maternal HIV viral load, placental malaria infection, episiotomy or perineal tear, and low birthweight. MTCT appears to be more common among mothers infected with subtype D compared with subtype A. Such differences in MTCT frequency may be caused by altered cellular tropism for placental cell types.

18 July 2003
Verified
Journal Article
Closed access
SFScott Filler
Scott Filler
LCLouise M Causer
Louise M Causer
RNRobert D Newman
Robert D Newman
ABAnn M Barber
Ann M Barber
JRJacquelin M Roberts
Jacquelin M Roberts
RSRichard W Steketee
Richard W Steketee